The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Immunosuppressive mechanisms in glioblastoma: Fig. 1.
Open accessAbstract
Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the failures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 2×
“For example, colony stimulating factor 1 (CSF-1), produced by gliomas,(15) has been shown to polarize the macrophage to a glioma-supportive M2 phenotype, which enhances glioma progression.(16) Furthermore, vascular endothelial growth factor not only increases glioma tumorigenicity and growth(17) – 20 but can also inhi…”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“The functional activity of the Tregs in the tumor microenvironment may be further enhanced by the activity of IDO, an intracellular enzyme overexpressed in many cancers, including gliomas, which suppresses T cell activation and proliferation by creating a tryptophan shortage.(58) Microglia and macrophages, the latter…”
BackgroundTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas
Komohara, Y., Ohnishi, K., Kuratsu, J., & Takeya, M. (2008) · The Journal of Pathology · doi:10.1002/path.2370 · Cited by 738
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu, A., Wei, J., Kong, L.-Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., & Heimberger, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq082 · Cited by 691
Self-citationThe Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Fecci, P. E., Mitchell, D. A., Whitesides, J. F., Xie, W., Friedman, A. H., Archer, G. E., Herndon, J. E., Bigner, D. D., Dranoff, G., & Sampson, J. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3773 · Cited by 617
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 585
Self-citationWainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Goldman, C. K., Kim, J., Wong, W. L., King, V, Brock, T., & Gillespie, G. Y. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.121 · Cited by 531
Ye, X.-Z., Xu, S.-L., Xin, Y.-H., Yu, S.-C., Ping, Y.-F., Chen, L., Xiao, H.-L., Wang, B., Yi, L., Wang, Q.-L., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103248 · Cited by 477
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
O'Farrell, A.-M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.4.1006 · Cited by 439
Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433
de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Wrann, M., Schlüsener, H., Seifert, J. M., Bodmer, S., Fontana, A., & Hofer, E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02700.x · Cited by 384
Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M., & Wiendl, H. (2003) · PubMed · Cited by 381
Self-citationGlioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.
Fontana, A., Hengartner, H., de Tribolet, N., & Weber, E. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.4.1837 · Cited by 366
Wintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366
Self-citationCancer immunoediting by the innate immune system in the absence of adaptive immunity
O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112738 · Cited by 348
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 347
Wrann, M., Bodmer, S., de Martin, R., Siepl, C., Hofer-Warbinek, R., Frei, K., Hofer, E., & Fontana, A. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02411.x · Cited by 332
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Heimberger, A. B., Abou-Ghazal, M., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 332
Self-citationHussain, S. F., Kong, L.-Y., Jordan, J., Conrad, C., Madden, T., Fokt, I., Priebe, W., & Heimberger, A. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1243 · Cited by 314
Self-citationWei, J., Barr, J., Kong, L.-Y., Wang, Y., Wu, A., Sharma, A. K., Gumin, J., Henry, V., Colman, H., Priebe, W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0734 · Cited by 282
Self-citationFlow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas
Badie, B., & Schartner, J. M. (2000) · Neurosurgery · doi:10.1097/00006123-200004000-00035 · Cited by 278
miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma
Wei, J., Wang, F., Kong, L.-Y., Xu, S., Doucette, T., Ferguson, S. D., Yang, Y., McEnery, K., Jethwa, K., Gjyshi, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4318 · Cited by 253
Self-citationRodrigues, J. C., Gonzalez, G. C., Zhang, L., Ibrahim, G., Kelly, J. J., Gustafson, M. P., Lin, Y., Dietz, A. B., Forsyth, P. A., Yong, V. W., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop023 · Cited by 244
Jordan, J. T., Sun, W., Hussain, S. F., DeAngulo, G., Prabhu, S. S., & Heimberger, A. B. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0336-x · Cited by 243
Self-citationRodon, J., Carducci, M. A., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 235
Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
Doucette, T., Rao, G., Rao, A., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M., & Heimberger, A. B. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0028 · Cited by 226
Self-citationHypoxia Potentiates Glioma-Mediated Immunosuppression
Wei, J., Wu, A., Kong, L.-Y., Wang, Y., Fuller, G., Fokt, I., Melillo, G., Priebe, W., & Heimberger, A. B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016195 · Cited by 220
Self-citationIntratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., & Becher, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130678 · Cited by 213
Self-citationSTAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression
Kohsaka, S., Wang, L., Yachi, K., Mahabir, R., Narita, T., Itoh, T., Tanino, M., Kimura, T., Nishihara, H., & Tanaka, S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0801 · Cited by 199
Sippel, T. R., White, J., Nag, K., Tsvankin, V., Klaassen, M., Kleinschmidt-DeMasters, B. K., & Waziri, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1107 · Cited by 195
(2002) · PubMed · Cited by 193
Kohanbash, G., McKaveney, K., Sakaki, M., Ueda, R., Mintz, A. H., Amankulor, N., Fujita, M., Ohlfest, J. R., & Okada, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4124 · Cited by 191
Abou-Ghazal, M., Yang, D. S., Qiao, W., Reina-Ortiz, C., Wei, J., Kong, L.-Y., Fuller, G. N., Hiraoka, N., Priebe, W., Sawaya, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1329 · Cited by 191
Self-citationCrane, C. A., Ahn, B. J., Han, S. J., & Parsa, A. T. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos014 · Cited by 169
Human Glioma-derived Interleukin-10 Inhibits Antitumor Immune Responses In Vitro
Hishii, M., Nitta, T., Ishida, H., Ebato, M., Kurosu, A., Yagita, H., Sato, K., & Okumura, K. (1995) · Neurosurgery · doi:10.1227/00006123-199512000-00016 · Cited by 160
Deryugina, E. I., Soroceanu, L., & Strongin, A. Y. (2002) · PubMed · Cited by 158
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients
Liu, Y., Carlsson, R., Ambjørn, M., Hasan, M., Badn, W., Darabi, A., Siesjö, P., & Issazadeh‐Navikas, S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5812-12.2013 · Cited by 151
Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70
Chahlavi, A., Rayman, P., Richmond, A. L., Biswas, K., Zhang, R., Vogelbaum, M., Tannenbaum, C., Barnett, G., & Finke, J. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4395 · Cited by 141
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors
Wainwright, D. A., Sengupta, S., Han, Y., & Lesniak, M. S. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor134 · Cited by 134
Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma
Xu, S., Wei, J., Wang, F., Kong, L.-Y., Ling, X.-Y., Nduom, E. K.-E., Gabrusiewicz, K. R., Doucette, T. A., Yang, Y., Yaghi, N. K., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju162 · Cited by 133
Self-citationUeda, R., Fujita, M., Zhu, X., Sasaki, K., Kastenhuber, E. R., Kohanbash, G., McDonald, H. A., Harper, J. W., Lonning, S. M., & Okada, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1067 · Cited by 121
Expression of Fas ligand by microglia: possible role in glioma immune evasion
Badie, B., Schartner, J. M., Prabakaran, S., Paul, J. S., & Vorpahl, J. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00361-7 · Cited by 119
Gielen, P. R., Schulte, B. M., Kers‐Rebel, E. D., Verrijp, K. C. N., Petersen-Baltussen, H. M. J. M., ter Laan, M., Wesseling, P., & Adema, G. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000183 · Cited by 117
Transforming growth factor-β pathway activity in glioblastoma
Frei, K., Gramatzki, D., Tritschler, I., Schroeder, J. J., Espinoza, L., Rushing, E. J., & Weller, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3467 · Cited by 110
Self-citationSampson, J. H., Schmittling, R. J., Archer, G. E., Congdon, K. L., Nair, S. K., Reap, E. A., Desjardins, A., Friedman, A. H., Friedman, H. S., Herndon, J. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031046 · Cited by 109
Fujita, M., Zhu, X., Sasaki, K., Ueda, R., Low, K. L., Pollack, I. F., & Okada, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2089 · Cited by 108
Selective expression of interleukin-10 gene within glioblastoma multiforme
Nitta, T., Hishii, M., Sato, K., & Okumura, K. (1994) · Brain Research · doi:10.1016/0006-8993(94)91055-3 · Cited by 107
Roth, P., Mittelbronn, M. G. A., Wick, W., Meyermann, R., Tatagiba, M. S., & Weller, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4783 · Cited by 105
Self-citationYan, J., Kong, L.-Y., Hu, J., Gabrusiewicz, K. R., Dibra, D., Xia, X., Heimberger, A. B., & Li, S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv137 · Cited by 104
Self-citationAvril, T., Saïkali, S., Vauléon, É., Jary, A., Hamlat, A., de Tayrac, M., Mosser, J., & Quillien, V. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.04.003 · Cited by 96
Zheng, Q., Han, L., Dong, Y., Tian, J., Huang, W., Liu, Z., Jia, X., Jiang, T., Zhang, J., Li, X., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou046 · Cited by 93
de Groot, J., Liang, J., Kong, L.-Y., Wei, J., Piao, Y., Fuller, G. N., Qiao, W., & Heimberger, A. B. (2012) · Oncotarget · doi:10.18632/oncotarget.663 · Cited by 91
Self-citationGlioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity
Verschuere, T., Toelen, J., Maes, W., Poirier, F., Boon, L., Tousseyn, T., Mathivet, T., Gerhardt, H., Mathieu, V., Robert Kiss, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28426 · Cited by 88
Glioblastoma Cancer Stem-Like Cells: Implications for Pathogenesis and Treatment
Nduom, E. K.-E., Hadjipanayis, C. G., & Meir, E. G. V. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182452e0d · Cited by 80
Self-citationColony stimulating factor-1 expression in human glioma
Alterman, R. L., & Stanley, E. R. (1994) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815350 · Cited by 72
Sai, K., Wang, S., Balasubramaniyan, V., Conrad, C. A., Lang, F. F., Aldape, K., Szymański, S., Fokt, I., Dasgupta, A., Madden, T. L., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0786-z · Cited by 71
Ball, S. L., Li, C., Li, P., & Lin, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018820 · Cited by 70
Activation of the NF-κB Pathway by the STAT3 Inhibitor JSI-124 in Human Glioblastoma Cells
McFarland, B. C., Gray, G. K., Nozell, S. E., Hong, S. W., & Benveniste, E. N. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0528 · Cited by 65
Kuppner, M. C., Sawamura, Y., Hamou, M., & de Tribolet, N. (1990) · Journal of neurosurgery · doi:10.3171/jns.1990.72.4.0619 · Cited by 64
Presence of immunosuppressive factors in brain-tumor cyst fluid
Kikuchi, K., & Neuwelt, E. A. (1983) · Journal of neurosurgery · doi:10.3171/jns.1983.59.5.0790 · Cited by 62
Enhanced immunosuppression by therapy‐exposed glioblastoma multiforme tumor cells
Authier, A., Farrand, K. J., Broadley, K. W. R., Ancelet, L. R., Hunn, M. K., Stone, S., McConnell, M. J., & Hermans, I. F. (2014) · International Journal of Cancer · doi:10.1002/ijc.29309 · Cited by 49
Aulwurm, S., Wischhusen, J., Friese, M. A., Borst, J. G., & Weller, M. (2005) · International Journal of Cancer · doi:10.1002/ijc.21544 · Cited by 42
Self-citationAshizawa, T., Akiyama, Y., Miyata, H., Iizuka, A., Komiyama, M., Kume, A., Omiya, M., Sugino, T., Asai, A., Hayashi, N., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2439 · Cited by 40
Hegardt, P., Widegren, B., & Sjögren, H. O. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1625 · Cited by 38
Regeneration and Tolerance Factor: A Novel Mediator of Glioblastoma-Associated Immunosuppression
Roth, P., Aulwurm, S., Gekel, I., Beier, D., Sperry, R. G., Mittelbronn, M. G. A., Meyermann, R., Beaman, K. D., Weller, M., & Wischhusen, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3062 · Cited by 22
Self-citationLiang, Q., Ma, C., Yang, Z., Gao, G., & Ma, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084723 · Cited by 19
Cited by
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Self-citationOverview of General and Discriminating Markers of Differential Microglia Phenotypes
Jurga, A. M., Paleczna, M., & Kuter, K. Z. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00198 · Cited by 1,000
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Self-citation
Metadata
- Authors
- Nduom, E. K., Weller, M., & Heimberger, A. B.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-10-29
- Volume
- 17
- Issue
- suppl 7
- Pages
- vii9-vii14
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2267280007
- Cited by
- 348
- References
- 88
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.